StockData
Nurix Therapeutics, Inc. logo

Nurix Therapeutics, Inc. (NRIX) stock

NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30
Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 13, 2026Score 15/3073% below fair value
$14.24−0.49 (-3.33%)

Close on Nov 17, 2026Market cap $1.56BP/E 6.2Yield 0.00%

Nurix Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Nurix Therapeutics's operating income for the twelve months ending Aug 31, 2026 was $289.66M. For fiscal 2025 it was -$285.67M. The highest annual figure on record is -$22.24M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Nov 30, 2025-$285.67M–
FY2024Nov 30, 2024-$213.03M–
FY2023Nov 30, 2023-$155.06M–
FY2022Nov 30, 2022-$183.87M–
FY2021Nov 30, 2021-$117.89M–
FY2020Nov 30, 2020-$64.98M–
FY2019Nov 30, 2019-$22.24M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ3 2026Aug 31, 2026$559.45M–
Q2 FY2026CQ2 2026May 31, 2026-$94.20M–
Q1 FY2026CQ1 2026Feb 28, 2026-$92.50M–
Q4 FY2025CQ4 2025Nov 30, 2025-$83.10M–
Q3 FY2025CQ3 2025Aug 31, 2025-$91.39M–
Q2 FY2025CQ2 2025May 31, 2025-$48.32M–
Q1 FY2025CQ1 2025Feb 28, 2025-$62.86M–
Q4 FY2024CQ4 2024Nov 30, 2024-$64.66M–
Q3 FY2024CQ3 2024Aug 31, 2024-$54.61M–
Q2 FY2024CQ2 2024May 31, 2024-$48.54M–
Q1 FY2024CQ1 2024Feb 29, 2024-$45.22M–
Q4 FY2023CQ4 2023Nov 30, 2023-$45.33M–
Q3 FY2023CQ3 2023Aug 31, 2023-$40.01M–
Q2 FY2023CQ2 2023May 31, 2023-$26.77M–
Q1 FY2023CQ1 2023Feb 28, 2023-$42.95M–
Q4 FY2022CQ4 2022Nov 30, 2022-$48.69M–
Q3 FY2022CQ3 2022Aug 31, 2022-$46.72M–
Q2 FY2022CQ2 2022May 31, 2022-$45.72M–
Q1 FY2022CQ1 2022Feb 28, 2022-$42.74M–
Q4 FY2021CQ4 2021Nov 30, 2021-$37.95M–
Q3 FY2021CQ3 2021Aug 31, 2021-$29.00M–
Q2 FY2021CQ2 2021May 31, 2021-$26.41M–
Q1 FY2021CQ1 2021Feb 28, 2021-$24.52M–
Q4 FY2020CQ4 2020Nov 30, 2020-$20.01M–
Q3 FY2020CQ3 2020Aug 31, 2020-$19.19M–
Q2 FY2020CQ2 2020May 31, 2020-$13.23M–
Q1 FY2020CQ1 2020Feb 29, 2020-$12.55M–
Q4 FY2019CQ4 2019Nov 30, 2019-$13.56M–
Q3 FY2019CQ3 2019Aug 31, 2019-$2.61M–

More Nurix Therapeutics figures

See a number that looks wrong?